EndoPredict vs OncoType Dx for BCPredictions

cp418

http://www.medscape.com/viewarticle/866023

EndoPredict vs OncoType Dx for Breast Cancer Predictions

BarredOwl

For those who don't wish to register for MedScape (although it is free and is an excellent resource), you can just google the title of the article provided by cp418 to access the full text.

Also, here is a link to the profiled research article:

"Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy"

Full text: http://jnci.oxfordjournals.org/content/108/11/djw149.full

You can access a pdf at that page as well.

BarredOwl

farmerlucy

Very interesting and good to know.

Fallleaves

Well this is good news. This seems to indicate that oncotype DX overestimated risk somewhat. So, using EndoPredict Clinical scores will identify more women as low-risk, who can safely avoid chemotherapy, thus reducing over-treatment.

SummerAngel

I read it as saying that the Oncotype underestimated risk.

• Only 5.8% of all patients identified as 'low risk' by EndoPredict developed secondary cancer compared with 10.1% of patients identified as 'low risk' by Oncotype DX
• Of the one-third of patients identified as having the lowest risks, those with low EndoPredict scores and whose disease hadn't already spread to their lymph nodes, just 0.5% developed second breast cancer after 10 years compared to 7% of those tested by Oncotype DX.

So 10.1% of patients who were identified as low risk by Oncotype developed secondary cancer.

I guess it's both, really, because EndoPredict proved to be more accurate in general.

Fallleaves

Thanks SummerAngel, I was looking at it wrong, I appreciate your setting me straight! It seems like EndoPredict plus clinical is very accurate. Wonder where it is available?